nach oben

International Journal of Clinical Oncology

Erschienen in:

20.02.2016 | Introduction to Invited Review Articles

Development and future directions of antiangiogenic therapy in hepatocellular carcinoma

verfasst von: Akinobu Taketomi

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Excerpt

Angiogenesis is a promising therapeutic target in treatments aimed at inhibiting tumor growth. Since the study published by Folkman in 1971 that demonstrated that tumor growth is angiogenesis-dependent [1], research has focused on identifying new therapeutic agents that can inhibit angiogenesis. In 2004, bevacizumab was developed as a potent inhibitor of vascular endothelial growth factor (VEGF), and this agent demonstrated modest antitumor activity when combined with chemotherapy. Currently, inhibition of angiogenesis has become a standard treatment option for several tumor types, including colorectal cancer, glioblastoma and ovarian cancer. …

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186CrossRefPubMed

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed

Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34CrossRefPubMed

Yamada K, Maishi N, Akiyama K et al (2015) CXCL12-CXCR7 axis is important for tumor endothelial cell angiogenic property. Int J Cancer 137:2825–2836CrossRefPubMed

Titel: Development and future directions of antiangiogenic therapy in hepatocellular carcinoma
verfasst von: Akinobu Taketomi
Publikationsdatum: 20.02.2016
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-0965-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Development and future directions of antiangiogenic therapy in hepatocellular carcinoma

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)

Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients

Growth rate of chemotherapy-naïve lung metastasis from colorectal cancer could be a predictor of early relapse after lung resection

Is scintigraphy necessary to detect migration of 125I seeds after brachytherapy for early prostate cancer?

A population-based study on the associations between chronic periodontitis and the risk of cancer

Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie